Physiology And Pathophysiology

Hemolytic disease of the fetus and newborn (HDFN)

HDFN occurs when maternal IgG antibody crosses the placenta and destroys fetal red cells bearing the corresponding paternally inherited antigen. Because only IgG crosses, ABO HDFN (anti-A,B from group O mothers) is common but usually mild, while anti-D and anti-Kell cause the most severe disease. Anti-Kell is distinctive: it not only hemolyzes cells but suppresses erythroid precursors in the marrow, so the bilirubin and reticulocyte response can underestimate severity.

Laboratory correlation: a positive DAT on cord blood, rising bilirubin, anemia, and a maternal IgG antibody identified by IAT confirm HDFN. The newborn workup includes ABO/Rh, DAT, and an eluate to identify the coating antibody.

Rh immune globulin and fetomaternal hemorrhage

Rh immune globulin (RhIG) is passive anti-D given to D-negative mothers to prevent active anti-D formation. The standard antepartum (28 weeks) and postpartum dose is 300 ug, which neutralizes 15 mL of D-positive fetal red cells (30 mL of fetal whole blood). Workup of a possible large bleed:

1. Rosette test — qualitative screen for fetomaternal hemorrhage; if negative, one vial covers it.
2. Kleihauer-Betke (acid elution) or flow cytometry — quantifies fetal cells when the rosette is positive.
3. Dose calculation: vials = (% fetal cells x 5000 mL maternal volume) / 30 mL per vial. Round up, then add one vial as a safety margin.

Worked example: a Kleihauer-Betke shows 1.2% fetal cells. Fetal bleed = 0.012 x 5000 = 60 mL. Vials = 60 / 30 = 2.0; round to 2, add 1 = 3 vials of RhIG. This calculation is a recurring MLS computation.

Autoimmune hemolytic anemias

The warm-versus-cold distinction drives the workup and is one of the most reliable theoretical-correlation items.

Resolving autoantibodies that mask alloantibodies

A strong autoantibody can react with all panel cells, hiding an underlying alloantibody that could cause a transfusion reaction. Techniques to unmask it:

• Warm autoadsorption removes autoantibody using the patient's own enzyme-treated cells (only valid if not transfused in the last 3 months, otherwise donor cells confound it).
• Allogeneic/differential adsorption uses reagent cells of selected phenotypes for recently transfused patients.
• Eluate recovers and identifies antibody bound to the patient's cells.
• Prewarm technique and cold autoadsorption neutralize cold autoantibodies so a 37 C-reactive alloantibody can be detected.

Drug-induced hemolysis and elution logic

Drug-induced immune hemolytic anemia produces a positive DAT through several mechanisms the exam contrasts: the drug-adsorption (hapten) type (classically high-dose penicillin) where antibody reacts only with drug-coated cells; the immune-complex type where the drug-antibody complex deposits and activates complement; and the autoantibody type (classically methyldopa, and many newer drugs) producing a true warm autoantibody indistinguishable from idiopathic warm AIHA. The workup adds drug-treated cells and drug in the test system to confirm specificity.

An eluate is the recovered antibody stripped from a patient's sensitized red cells, and its interpretation is diagnostic: in HDFN the eluate identifies the maternal antibody (e.g., anti-D), in a delayed hemolytic reaction it reveals the anamnestic alloantibody, and in warm AIHA it shows broad, panreactive IgG. Knowing what an eluate should contain in each scenario is a frequent correlation item.

Putting the correlation logic together

The exam's recurring physiology logic flows in four steps. First, identify the antibody's class and thermal range from the serologic data. Second, predict the disease — IgG crossing the placenta points to HDFN, 37 C-reactive IgG with an anti-IgG DAT points to warm AIHA, and cold IgM with a C3d-only DAT points to cold agglutinin disease. Third, compute RhIG when a D-negative mother has a measured fetomaternal bleed, remembering the round-up-then-add-one convention.

Fourth, select the adsorption or elution method that exposes a clinically significant alloantibody hidden beneath an autoantibody, mindful that recent transfusion forbids warm autoadsorption and mandates differential allogeneic adsorption. Mastering this chain — from a positive DAT through monospecific reagents, eluate, and adsorption to a transfusion decision — is what separates a passing Blood Banking performance from rote memorization on the computer adaptive MLS exam.

Antenatal monitoring and prevention

Managing an alloimmunized pregnancy is a recurring correlation theme. Once a clinically significant maternal IgG antibody is identified, the lab follows a titer at intervals; a critical titer (commonly 16 or 32 for anti-D) prompts referral for fetal monitoring such as middle cerebral artery Doppler. Prevention remains the priority: routine antepartum RhIG at 28 weeks and again postpartum within 72 hours for D-negative mothers carrying or delivering a D-positive infant, plus extra doses after amniocentesis, abortion, or trauma.

A positive postpartum maternal antibody screen showing passive anti-D from RhIG must be distinguished from active immunization, because the management diverges sharply. Tying titer trends, RhIG timing, and the fetal-bleed quantitation together is the kind of multistep reasoning the MLS exam favors.